BofA reinstated coverage of Johnson & Johnson with a Neutral rating and $166 price target The current valuation at a premium to other drug names “seems likely to cap upside,” the analyst tells investors while reinstating coverage of 11 large-cap U.S. pharma and biotech stocks. J&J has a “fairly interesting pipeline” and talc litigation resolution in 2025 “would help,” the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- J&J’s CARVYKTI shows higher rates of minimal residual disease negativity
- Gilead price target raised to $115 from $105 at Oppenheimer
- J&J announces new frontline data featuring TECVAYLI fro 2 studies in NDMM
- J&J trial news may have positive read for Neumora Therapeutics, says RBC Capital
- J&J seeks U.S. FDA approval for pediatric indications for TREMFYA